Loading patent…
AssigneesInstitute Pasteur, New York University
InventorsShirley Longacre-Andre, Charles Roth, Faridabano Nato, John W. Barnwell, Kamini Mendis
Estimating the term…
The invention relates to a recombinant protein fabricated in a baculovirus system, of which the essential constitutive polypeptide sequence is that of a C-terminal fragment of 19 kilodalton (p19) of the surface protein 1 (protein MSP-1) of the merozoite parasite of the Plasmodium type, particularly Plasmodium falciparum, which is infectious for humans, said C-terminal fragment remaining normally anchored at the surface of the parasite at the end of its penetration phase into human erythrocytes, in the occurrence of an infectious cycle. Said recombinant protein is applicable to the production of vaccines against malaria.
A baculovirus vector selected from the group consisting of PfMSP1p19A deposited at the CNCM under No. I-1661, PfMSP1p19S deposited at the CNCM under No. I-1662, and PcMSP1p19S deposited at the CNCM under No. I-1663.
A baculovirus vector comprising:
A baculovirus vector comprising a promoter and a synthetic nucleoitde sequence comprising SEQ ID NO:7.
A baculovirus vector comprising:
A baculovirus vector comprising:
A baculovirus vector comprising:
A baculovirus vector comprising:
A synthetic polynucleotide comprising a synthetic sequence encoding a 19 kilodalton C-terminal fragment of a Plasmodium falciparum meroxoite surface protein 1 (MSP-1) having a total GC content of 40% to 60%, wherein said synthetic sequence is contained in a baculovirus vector selected from the group consisting of PfMSP1p19A deposited at the CNCM under No. I-1661, PfMSP1p19S deposited at the CNCM under No. I-1662, wherein said synthetic polynucleotide further comprises a polynucleotide encoding a signal peptide of a Plasmodium MSP-1 protein.
Dependencies are inferred from the claim text.